Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis

FPB KroonDepartment of Rheumatology, Leiden University Medical Center, Leiden, The NetherlandsCorrespondence[email protected]
View further author information

AC Bay-JensenBiomarker and Research, Nordic Bioscience, Herlev, DenmarkView further author information

R WittoekDepartment of Rheumatology, Ghent University Hospital, Ghent, BelgiumView further author information

G VerbruggenDepartment of Rheumatology, Ghent University Hospital, Ghent, BelgiumView further author information

JS SmolenDivision of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, AustriaView further author information

M KloppenburgDepartment of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands;Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The NetherlandsView further author information

R RamondaRheumatology Unit, Department of Medicine DIMED, University of Padua, Padua, ItalyView further author information

show all

"Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis." Scandinavian Journal of Rheumatology, 49(2), pp. 167–168

Acknowledgement

This study was funded by Pfizer.

Disclosure statement

MK reports an unrestricted grant paid to the institution and study medication free of charge from Pfizer (Wyeth) during the conduct of the study, outside the submitted work. MK reports advisory board fees from Levicept, GlaxoSmithKline, AbbVie, Merck, and Pfizer, grants from IMI-EFpIA ApproACH, grants from Pfizer, and other from AbbVie. ACBJ is a full-time employee and holds shares at Nordic Bioscience. The other authors have no potential conflicts of interest to report.

Additional information

Funding

This work was supported by This study was funded by Pfizer

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis

Information for

Open access

Opportunities

Help and information

Etanercept therapy leads to reductions in matrix metalloproteinase-3 in patients with erosive hand osteoarthritis

Acknowledgement

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature